Your Speakers
Billur Tugce Cinar
Billur Tugce Cinar is a Clinical Project Lead at Novo Nordisk. She is accountable for the succefful planning, execution and completion of several of the trials within the REIMAGINE programme. Previous to this, she was Clinical Operations Lead, working on the CagriSema type 2 diabetes phase 3 programme, where she drove forward several important activities from early start up. Prior to moving to Denmark, Tugce worked for the Novo Nordisk Turkish affiliate for many years in several positions and also managed trials in multiple indications within several countries as a trial manager, with more than 17 years of experience within clinical research.
Christoffer Andersen Hagemann
Christoffer Andersen Hagemann is an Associate International Medical Director at Novo Nordisk A/S. He has been a medical specialist in the clinical development of CagriSema for the management of obesity and type 2 diabetes at Novo Nordisk. He earned his degree in medicine from the University of Copenhagen, Denmark, and also a PhD on bariatric surgery, obesity and gut hormones from the University of Copenhagen. Christoffer has a background as a medical doctor and 4 years of experience in clinical drug development across phase 1 and 3 trials working with amylin analogues.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla eget laoreet neque. Nunc mollis quam eu neque pulvinar, vitae mollis eros molestie. Nullam bibendum erat nec ornare consectetur. Sed faucibus mi et consequat rutrum. Vestibulum vitae lacus libero. Quisque eleifend dictum risus, ut luctus velit elementumn
Etiam ut dignissim nibh. Aenean vestibulum placerat aliquet. Maecenas eget mi mi. Nullam dignissim tincidunt vestibulum. Pellentesque ultrices varius mattis. Duis a aliquam lacus, quis fermentum lacus
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla eget laoreet neque. Nunc mollis quam eu neque pulvinar, vitae mollis eros molestie. Nullam bibendum erat nec ornare consectetur. Sed faucibus mi et consequat rutrum. Vestibulum vitae lacus libero. Quisque eleifend dictum risus, ut luctus velit elementumn
Etiam ut dignissim nibh. Aenean vestibulum placerat aliquet. Maecenas eget mi mi. Nullam dignissim tincidunt vestibulum. Pellentesque ultrices varius mattis. Duis a aliquam lacus, quis fermentum lacus
Jan Grabowski
Jan Grabowski is a Global Trial Manager at the headquarters of Novo Nordisk in Copenhagen, Denmark. Prior to this, he held various Trial Manager and Clinical Research Associate roles within the Clinical Development Centre for Novo Nordisk Pharma in Poland. Jan is experienced in project planning, management and execution, from site selection to post-clinical trial activities for phase 3 trials. He has worked in the areas of strategy, recruitment, retention, budgeting, risk analysis and management and has also been the manager of clinical trial teams. Jan has worked primarily in the areas of cardiovascular disease, heart failure and rare disease. He gained his Master’s degree in Environmental Protection from the Higher School of Ecology and Management in Warsaw and gained his Bachelor’s degree in engineering from Warsaw University of Life Sciences in Poland.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla eget laoreet neque. Nunc mollis quam eu neque pulvinar, vitae mollis eros molestie. Nullam bibendum erat nec ornare consectetur. Sed faucibus mi et consequat rutrum. Vestibulum vitae lacus libero. Quisque eleifend dictum risus, ut luctus velit elementumn
Etiam ut dignissim nibh. Aenean vestibulum placerat aliquet. Maecenas eget mi mi. Nullam dignissim tincidunt vestibulum. Pellentesque ultrices varius mattis. Duis a aliquam lacus, quis fermentum lacus
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla eget laoreet neque. Nunc mollis quam eu neque pulvinar, vitae mollis eros molestie. Nullam bibendum erat nec ornare consectetur. Sed faucibus mi et consequat rutrum. Vestibulum vitae lacus libero. Quisque eleifend dictum risus, ut luctus velit elementumn
Etiam ut dignissim nibh. Aenean vestibulum placerat aliquet. Maecenas eget mi mi. Nullam dignissim tincidunt vestibulum. Pellentesque ultrices varius mattis. Duis a aliquam lacus, quis fermentum lacus
Tsinat Berhane
Tsinat Berhane is a Global Trial Manager at Novo Nordisk. In her current role, Tsinat is responsible for driving activities during the planning, execution, and finalisation of the REIMAGINE trials, mainly REIMAGINE 5 and REIMAGINE SWITCH. Tsinat has a background within biomedicine and joined Novo Nordisk in 2023. Prior to that, she worked as a drug discovery specialist, driving early research activities.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla eget laoreet neque. Nunc mollis quam eu neque pulvinar, vitae mollis eros molestie. Nullam bibendum erat nec ornare consectetur. Sed faucibus mi et consequat rutrum. Vestibulum vitae lacus libero. Quisque eleifend dictum risus, ut luctus velit elementumn
Etiam ut dignissim nibh. Aenean vestibulum placerat aliquet. Maecenas eget mi mi. Nullam dignissim tincidunt vestibulum. Pellentesque ultrices varius mattis. Duis a aliquam lacus, quis fermentum lacus
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla eget laoreet neque. Nunc mollis quam eu neque pulvinar, vitae mollis eros molestie. Nullam bibendum erat nec ornare consectetur. Sed faucibus mi et consequat rutrum. Vestibulum vitae lacus libero. Quisque eleifend dictum risus, ut luctus velit elementumn
Etiam ut dignissim nibh. Aenean vestibulum placerat aliquet. Maecenas eget mi mi. Nullam dignissim tincidunt vestibulum. Pellentesque ultrices varius mattis. Duis a aliquam lacus, quis fermentum lacus
Xi Fu
Xi Fu is a Senior Safety Surveillance Advisor at Novo Nordisk, based in Denmark. She is involved with pharmacovigilance surveillance for CagriSema clinical trials in type 2 diabetes and has worked across REDEFINE 5 and all of the REIMAGINE trials. She has experience in both safety operations and safety surveillance in the areas of single case review, signal management and monitoring, clinical trial protocol development, investigator meetings, trial conduct, trial data interpretation, submission activities for regulatory approvals and health authority interaction.
Prior to her roles in pharmacovigilance, Xi was a Visiting Researcher studying obesity and glucagon-like peptide-1 therapies at the Department of Biomedical Sciences and Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen, Denmark. Xi was a medical doctor and paediatrician, with over 7 years of medical experience in clinical consultations, having worked and been trained at a number of university hospitals in China.
She has several peer-reviewed publications and gained her PhD in Paediatrics from the Tongji Medical College of Huazhong University of Science and Technology in China. She enjoys working with cross-geographical, cross-cultural and cross-functional teams.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla eget laoreet neque. Nunc mollis quam eu neque pulvinar, vitae mollis eros molestie. Nullam bibendum erat nec ornare consectetur. Sed faucibus mi et consequat rutrum. Vestibulum vitae lacus libero. Quisque eleifend dictum risus, ut luctus velit elementumn
Etiam ut dignissim nibh. Aenean vestibulum placerat aliquet. Maecenas eget mi mi. Nullam dignissim tincidunt vestibulum. Pellentesque ultrices varius mattis. Duis a aliquam lacus, quis fermentum lacus
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla eget laoreet neque. Nunc mollis quam eu neque pulvinar, vitae mollis eros molestie. Nullam bibendum erat nec ornare consectetur. Sed faucibus mi et consequat rutrum. Vestibulum vitae lacus libero. Quisque eleifend dictum risus, ut luctus velit elementumn
Etiam ut dignissim nibh. Aenean vestibulum placerat aliquet. Maecenas eget mi mi. Nullam dignissim tincidunt vestibulum. Pellentesque ultrices varius mattis. Duis a aliquam lacus, quis fermentum lacus
Xia He
Xia He is Clinical Operations Lead at Novo Nordisk in Copenhagen, Denmark. In this role, she oversees high-priority clinical trial programmes across diabetes and rare blood disorders, ensuring internal teams and external partners adhere to timelines, budgets and quality standards. She also provides insights into complex trial data and leads cross-functional initiatives to streamline operational efficiency, across diverse geographies. Xia has over 10 years of experience in the end-to-end management of complex phase 1–3 metabolic disease, oncology and rare disease clinical trials across the globe.
This has involved trial monitoring and oversight, risk identification, budget management, the setting up of operational teams, investigator liaison, and support of marketing and commercial activities. Xia completed her BSc in Pharmaceutical Science at Shenyang Pharmaceutical University and her Master’s degree in Chemical Biology at Peking University, China. Xia is passionate about advancing innovative medicine and improving patient outcomes.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla eget laoreet neque. Nunc mollis quam eu neque pulvinar, vitae mollis eros molestie. Nullam bibendum erat nec ornare consectetur. Sed faucibus mi et consequat rutrum. Vestibulum vitae lacus libero. Quisque eleifend dictum risus, ut luctus velit elementumn
Etiam ut dignissim nibh. Aenean vestibulum placerat aliquet. Maecenas eget mi mi. Nullam dignissim tincidunt vestibulum. Pellentesque ultrices varius mattis. Duis a aliquam lacus, quis fermentum lacus
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla eget laoreet neque. Nunc mollis quam eu neque pulvinar, vitae mollis eros molestie. Nullam bibendum erat nec ornare consectetur. Sed faucibus mi et consequat rutrum. Vestibulum vitae lacus libero. Quisque eleifend dictum risus, ut luctus velit elementumn
Etiam ut dignissim nibh. Aenean vestibulum placerat aliquet. Maecenas eget mi mi. Nullam dignissim tincidunt vestibulum. Pellentesque ultrices varius mattis. Duis a aliquam lacus, quis fermentum lacus